700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 1,543
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ms. Elaine O'Hara | Executive VP & Chief Strategy Officer | N/D | N/D | 1968 |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
La calificación ISS Governance QuickScore de Novavax, Inc. a partir del 1 de mayo de 2024 es 5. Las puntuaciones principales son Auditoría: 7; Junta: 4; Derechos del accionista: 5; Compensación: 5.